What is a stock summary page? Click here for an overview.
Business Description
Amarin Corp PLC
NAICS : 325412
SIC : 2834
ISIN : US0231112063
Share Class Description:
AMRN: ADRDescription
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 35.49 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -2.21 | |||||
| Beneish M-Score | -2.61 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -27.3 | |||||
| 3-Year FCF Growth Rate | 23 | |||||
| 3-Year Book Growth Rate | -11.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 34.32 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.41 | |||||
| 9-Day RSI | 55.66 | |||||
| 14-Day RSI | 55.32 | |||||
| 3-1 Month Momentum % | -19.91 | |||||
| 6-1 Month Momentum % | -1.9 | |||||
| 12-1 Month Momentum % | -47.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.53 | |||||
| Quick Ratio | 2.55 | |||||
| Cash Ratio | 1.74 | |||||
| Days Inventory | 546.43 | |||||
| Days Sales Outstanding | 198.14 | |||||
| Days Payable | 130.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | 0.41 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 34.85 | |||||
| Operating Margin % | -44.36 | |||||
| Net Margin % | -41.07 | |||||
| FCF Margin % | -14.42 | |||||
| ROE % | -16.98 | |||||
| ROA % | -11.94 | |||||
| ROIC % | -42.13 | |||||
| 3-Year ROIIC % | 182.05 | |||||
| ROC (Joel Greenblatt) % | -53.39 | |||||
| ROCE % | -14.98 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.03 | |||||
| PB Ratio | 0.46 | |||||
| Price-to-Tangible-Book | 0.48 | |||||
| EV-to-EBIT | 0.69 | |||||
| EV-to-EBITDA | 0.71 | |||||
| EV-to-Revenue | -0.26 | |||||
| EV-to-Forward-Revenue | 1.34 | |||||
| EV-to-FCF | 1.8 | |||||
| Price-to-GF-Value | 0.93 | |||||
| Price-to-Median-PS-Value | 0.25 | |||||
| Price-to-Net-Current-Asset-Value | 0.56 | |||||
| Price-to-Net-Cash | 2.18 | |||||
| Earnings Yield (Greenblatt) % | 144.93 | |||||
| FCF Yield % | -14.19 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers